Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

QR Code

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Diabetic macular edema (DME) is the main cause of visual loss in patients with diabetic retinopathy. DME has been treated using intravitreal anti-vascular endothelial growth factor (VEGF) drugs, steroids, laser photocoagulation, vitreoretinal surgery, and their combinations. These modalities are gen...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ren Aoki, Makoto Hatano, Fumiaki Higashijima, Takuya Yoshimoto, Masanori Mikuni, Tadahiko Ogata, Yuka Kobayashi, Makiko Wakuta, Kazuhiro Kimura
Format:	article
Langue:	EN
Publié:	Karger Publishers 2021
Sujets:	tissue plasminogen activator diabetic macular edema vitrectomized eye central retinal thickness visual acuity Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/a7bc3bcbc55f46a5a30e91fc8cfbb2e9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
par: Kumagai K, et autres
Publié: (2019)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
par: Pessoa B, et autres
Publié: (2021)

Pars Planectomy: Preliminary Report of a New Glaucoma Filtering Technique in Vitrectomized Eyes
par: Wangsupadilok B, et autres
Publié: (2021)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
par: Tran THC, et autres
Publié: (2021)

Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy
par: Chiara Altana, et autres
Publié: (2021)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
par: Dweikat A, et autres
Publié: (2021)

Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region
par: Wei W, et autres
Publié: (2021)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
par: Zarranz-Ventura J, et autres
Publié: (2020)

PLASMINOGEN ACTIVATOR OF YERSINIA PESTIS
par: V. V. Evseeva, et autres
Publié: (2015)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
par: Coelho J, et autres
Publié: (2019)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
par: Campos Polo R, et autres
Publié: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2018)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
par: Zarranz-Ventura J, et autres
Publié: (2020)

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review
par: Belal M Firwana, et autres
Publié: (2011)

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes
par: Udaondo P, et autres
Publié: (2021)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
par: Fouda SM, et autres
Publié: (2017)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
par: Van Aken E, et autres
Publié: (2020)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
par: Thomas BJ, et autres
Publié: (2016)

Inhibition of epithelial–mesenchymal transition in retinal pigment epithelial cells by a retinoic acid receptor-α agonist
par: Yuka Kobayashi, et autres
Publié: (2021)

Effect of Tissue Plasminogen Activator on Treatment Outcome and Neuronal Degeneration in Acute Ischemic Stroke
par: Muhammad Masoud, et autres
Publié: (2021)

Benzalkonium chloride-induced myofibroblastic transdifferentiation of Tenon’s capsule fibroblasts is inhibited by coculture with corneal epithelial cells or by interleukin-10
par: Chiemi Yamashiro, et autres
Publié: (2021)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
par: Paulose R, et autres
Publié: (2016)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
par: Joshi L, et autres
Publié: (2016)

Edema hemorrágico agudo del lactante: reporte de un caso de presentación atípica
par: Yarmuch G,Paula, et autres
Publié: (2012)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
par: Kiire CA, et autres
Publié: (2015)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
par: Dugel PU, et autres
Publié: (2016)

Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma
par: Yichao Wang, et autres
Publié: (2021)

Edema fisiológico del recién nacido
par: ORTEGA,RAUL, et autres
Publié: (1947)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
par: Ivanovska Adjievska B, et autres
Publié: (2017)

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
par: Lehmann R, et autres
Publié: (2021)

A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE)
par: Larsen J, et autres
Publié: (2021)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
par: Ume Sughra, et autres
Publié: (2021)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
par: Zola M, et autres
Publié: (2017)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
par: Chen YX, et autres
Publié: (2020)

Experiencia de trombolisis sistematizada en infarto cerebral agudo en un hospital público de Chile
par: Figueroa-Reyes,Tatiana, et autres
Publié: (2011)

Clinical therapeutic effects of intravitreal injection of Conbercept for macular edema in different types of retinal vein occlusion
par: Peng-Yao Lin, et autres
Publié: (2021)

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
par: Iannetta D, et autres
Publié: (2021)

Edema pulmonar de gran altura
par: UNDURRAGA M,FELIPE, et autres
Publié: (2003)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
par: Kartasasmita A, et autres
Publié: (2019)